Taking the Temperature of 3 Ebola-Related Stocks

After a brief hiatus from the headlines, Ebola -- and the companies helping to fight the disease -- are back at the forefront

Jan 7, 2015 at 10:07 AM
facebook X logo linkedin

When news of the first confirmed domestic case of Ebola hit the headlines last fall, markets sold off in mayhem. Various drugmakers, however, were able to capitalize off the fears, including Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and NewLink Genetics Corp (NASDAQ:NLNK). In fact, on Oct. 1 -- when the aforementioned news broke -- these stocks tacked on respective single-session gains of 18.2%, 3.8%, and 7.1%.

Although Ebola hit the backburner for a short time amid earnings season and crude oil's crash, suspected diagnoses from overseas -- and Johnson & Johnson's (NYSE:JNJ) announcement yesterday that it has begun human testing of its vaccine for the virus -- have brought it back to the forefront. As such, it appears to be an opportune time to revisit the names that were front and center on the newswires just three months ago.

Tekmira Pharmaceuticals Corporation

Despite its initial surge in early October, TKMR has run out of steam, and is down 40% from its Oct. 1 close at $24.99 to trade at $15.04. Assisting the stock in its trek lower has been its 50-day moving average, and despite a recent attempt to topple this trendline in the wake of a well-received update on its cancer drug, TKM-PLK1, the stock has not finished a session north of here since Oct. 17.

Option traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have kept the faith, though, and over the past 10 sessions, have bought to open 6.76 calls for every put. Echoing this is the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.29, which indicates call open interest more than triples put open interest among options set to expire in three months or less. There could be an ulterior motive to this recent glut of call buying, however, as more than 10% of the security's float is sold short.

BioCryst Pharmaceuticals, Inc.

BCRX has put in a much stronger showing than its sector peer, and has tacked on 19% since its Oct. 1 settlement at $10.15 to linger near $12.08. More recently, the stock has caught a lift from its 10-day moving average -- as well as news that its antiviral drug, BCX4430, was effective in fighting the Ebola virus in monkeys -- since mid-December.

Option players have been quick to pick up long calls on BCRX over the past two weeks, as evidenced by the stock's 10-day ISE/CBOE/PHLX call/put volume ratio of 15.19, which ranks in the 85th annual percentile. With more than one-fifth of the equity's available float sold short, though, a portion of this call buying may have been at the hands of short sellers hedging against any additional upside.

NewLink Genetics Corp

NLNK has by far been the best performer among the group. Although the stock has sold off sharply this week -- despite reports the company will resume testing its Ebola vaccine in Geneva -- it appears to have found a foothold atop its 20-day moving average, and is still up 65.6% from its Oct. 1 finish at $22.95 to trade at $38.00.

Should the equity resume its longer-term uptrend, an unwinding of the skepticism surrounding it could translate into tailwinds. At the ISE, CBOE, and PHLX, for example, NLNK's 10-day put/call volume ratio of 0.39 rests in the bearishly skewed 65th percentile of its annual range. Elsewhere, 27.3% of the stock's float is sold short, representing nearly three weeks' worth of pent-up buying demand, at average daily trading levels.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI